듀셴형 근이영양증(DMD) 신규 치료법 : 2026년 2분기

The Global Duchenne Muscular Dystrophy Emerging Therapies Market is expected to increase at a CAGR of 10.0% for the forecast period, growing from USD 0.45 billion in 2026 to 1.06 USD billion by 2035.

Duchenne Muscular Dystrophy is a severe, progressive, X-linked genetic disorder caused by mutations in the dystrophin gene, resulting in the absence of functional dystrophin protein. The disease primarily affects boys and leads to progressive muscle degeneration, loss of ambulation, respiratory complications, cardiomyopathy, and premature mortality. Historically, treatment options have focused on corticosteroids and supportive care aimed at slowing disease progression and improving quality of life. However, recent advances in molecular biology, genetic engineering, and targeted therapeutics have transformed the DMD treatment landscape.

Emerging therapies analysis has become increasingly important as pharmaceutical companies, biotechnology firms, investors, healthcare providers, and regulatory authorities seek to evaluate pipeline developments, therapeutic mechanisms, clinical progress, competitive positioning, and future commercialization opportunities. The growing number of investigational therapies targeting dystrophin restoration, gene correction, exon skipping, and muscle regeneration is creating significant demand for comprehensive emerging therapy intelligence.

Market Drivers

Advancements in Gene Therapy Technologies

One of the primary drivers of market growth is the rapid progress in gene therapy development. Researchers are increasingly utilizing adeno-associated virus (AAV) vectors and micro-dystrophin technologies to address the underlying genetic defect responsible for DMD.

Gene therapy approaches have demonstrated the potential to provide long-term therapeutic benefits through dystrophin replacement, significantly increasing industry investment and clinical development activity. Improvements in vector engineering and delivery technologies continue to expand therapeutic possibilities within the DMD pipeline.

Expansion of Precision Medicine Approaches

Precision medicine is transforming DMD treatment by enabling the development of therapies targeting specific genetic mutations. Exon-skipping therapies, mutation-specific treatments, and RNA-based technologies are providing more personalized treatment strategies for defined patient populations.

The increasing availability of genetic testing and molecular diagnostics is supporting patient identification and driving demand for genotype-specific therapeutic development programs.

Strong Orphan Drug Development Incentives

DMD qualifies for orphan drug designation in major pharmaceutical markets, providing developers with regulatory incentives such as market exclusivity, tax benefits, fee reductions, and accelerated review pathways.

These incentives have significantly improved the commercial attractiveness of DMD therapeutic development and encouraged greater participation from biotechnology companies and specialty pharmaceutical organizations.

Growing Rare Disease Research Investments

Governments, research foundations, patient advocacy organizations, and private investors continue to increase funding for rare disease programs. DMD remains a major focus area due to its severe clinical burden and substantial unmet medical need.

Increasing research investment is accelerating clinical trial activity, biomarker development, translational research, and novel therapeutic discovery across the DMD treatment landscape.

Market Restraints

High Development and Manufacturing Costs

Many emerging DMD therapies involve complex biological manufacturing processes, particularly gene therapies and advanced genetic medicines. Production of viral vectors and specialized biologics requires substantial capital investment and highly specialized manufacturing infrastructure.

These factors contribute to elevated development costs and may create barriers to widespread commercialization.

Clinical Development Challenges

The rarity of DMD and the complexity of disease progression create significant clinical development challenges. Patient recruitment can be difficult, and demonstrating long-term clinical efficacy often requires extended study durations.

Variability in disease progression and the absence of universally accepted surrogate endpoints can further complicate regulatory evaluations.

Safety and Regulatory Uncertainties

Advanced therapeutic modalities, particularly gene therapies, face ongoing safety evaluation requirements. Long-term monitoring of treatment durability, immune responses, and potential adverse events remains essential for regulatory approval and commercialization.

Regulatory expectations continue to evolve as agencies assess the long-term risk-benefit profiles of innovative DMD therapies.

Technology and Segment Insights

The global Duchenne Muscular Dystrophy emerging therapies analysis market can be segmented by therapeutic approach, development phase, mechanism of action, molecule type, sponsor type, end user, and geography.

By therapeutic approach, the market includes gene therapies, exon-skipping therapies, antisense oligonucleotides, gene-editing therapies, cell therapies, mutation suppression therapies, anti-inflammatory therapies, muscle regeneration therapies, and combination approaches. Gene therapies represent one of the most transformative segments due to their potential to address the root cause of disease through dystrophin restoration.

By development phase, the market includes preclinical programs, Phase I trials, Phase II trials, Phase III trials, and regulatory-stage candidates. Late-stage clinical programs attract significant attention due to their proximity to commercialization and potential impact on future treatment standards.

By mechanism of action, the market includes dystrophin replacement, exon skipping, gene correction, mutation suppression, muscle preservation, anti-fibrotic therapies, anti-inflammatory interventions, and regenerative medicine approaches. Dystrophin restoration remains a primary focus of emerging therapeutic development because it directly targets the underlying genetic deficiency responsible for DMD.

By molecule type, the market includes viral vector therapies, antisense oligonucleotides, monoclonal antibodies, small molecules, RNA-based therapeutics, and cellular therapies. Antisense oligonucleotides continue to represent a major segment due to their established role in exon-skipping treatment strategies.

By sponsor type, the market includes pharmaceutical companies, biotechnology firms, academic institutions, government-funded research organizations, and collaborative research consortia. Biotechnology companies play a particularly important role due to their focus on innovative genetic medicine platforms and rare disease specialization.

By end user, the market serves pharmaceutical companies, biotechnology developers, contract research organizations, investors, academic researchers, healthcare providers, and market intelligence firms. Pharmaceutical and biotechnology organizations account for a substantial share of demand due to their ongoing pipeline assessment and competitive intelligence requirements.

Technological innovations are significantly enhancing therapeutic development through advanced genomic sequencing, artificial intelligence-assisted drug discovery, CRISPR-based gene editing, next-generation vector engineering, digital biomarkers, wearable monitoring systems, and real-world evidence platforms. These technologies are improving patient selection, treatment monitoring, clinical trial efficiency, and therapeutic optimization.

Geographically, North America dominates the market due to strong rare disease research infrastructure, significant biotechnology investment, supportive regulatory frameworks, and extensive clinical trial activity. Europe maintains a substantial market share supported by advanced healthcare systems and orphan drug incentives. Asia-Pacific is expected to experience rapid growth owing to expanding biotechnology capabilities, increasing healthcare investments, improving genetic diagnostics, and growing participation in global clinical research programs. Latin America and the Middle East & Africa are gradually improving rare disease awareness and access to specialized healthcare services.

Competitive and Strategic Outlook

The competitive landscape is highly dynamic as pharmaceutical companies and biotechnology firms compete to develop transformative therapies capable of modifying or correcting the underlying pathology of DMD. Competition is centered on therapeutic efficacy, durability of response, safety profile, patient eligibility, manufacturing scalability, and regulatory success.

Organizations are actively pursuing strategic collaborations, licensing agreements, acquisition activities, and research partnerships to strengthen technological capabilities and accelerate development timelines. The industry is increasingly focused on expanding treatment eligibility beyond mutation-specific populations and developing therapies capable of benefiting broader patient groups.

Emerging therapies are also shifting the market from symptomatic management toward disease modification and potential long-term functional improvement. Companies capable of demonstrating meaningful clinical benefits, durable dystrophin expression, and favorable safety outcomes are expected to secure strong competitive positions in the evolving DMD treatment landscape.

Conclusion

The global Duchenne Muscular Dystrophy emerging therapies analysis market is poised for substantial growth through 2031, supported by rapid advances in gene therapy, precision medicine, exon-skipping technologies, and rare disease research. The increasing number of innovative therapeutic candidates targeting the underlying genetic causes of DMD is transforming the future outlook for patients and healthcare providers. Although challenges related to manufacturing complexity, clinical development risks, regulatory uncertainty, and long-term safety monitoring remain, continued scientific progress and expanding investment activity are expected to accelerate therapeutic innovation and create significant opportunities across the DMD treatment ecosystem.

Key Benefits of this Report

• Insightful Analysis: Detailed market insights across regions, customer segments, policies, socio-economic factors, consumer preferences, and industry verticals.
• Competitive Landscape: Understand strategic moves by key players to identify optimal market entry approaches.
• Market Drivers and Future Trends: Assess major growth forces and emerging developments shaping the market.
• Actionable Recommendations: Support strategic decisions to unlock new revenue streams.
• Caters to a Wide Audience: Suitable for startups, research institutions, consultants, SMEs, and large enterprises.

What Businesses Use Our Reports For

Industry and market insights, opportunity assessment, product demand forecasting, market entry strategy, geographical expansion, capital investment decisions, regulatory analysis, new product development, and competitive intelligence.

Report Coverage

• Historical data from 2021 to 2024, Base year 2025, and Forecast years from 2026 to 2031
• Growth opportunities, challenges, supply chain outlook, regulatory framework, and trend analysis
• Competitive positioning, strategies, and market share evaluation, and trade analysis
• Revenue growth and forecast assessment across segments and regions
• Company profiling including strategies, products, financials, and key developments

TABLE OF CONTENTS

1. Executive Summary

• 1.1 Market Overview
• 1.2 Duchenne Muscular Dystrophy (DMD) Disease Burden Overview
• 1.3 Key Findings and Strategic Insights
• 1.4 Emerging Therapy Landscape Snapshot
• 1.5 Commercial Opportunity Assessment
• 1.6 Key Pipeline Highlights
• 1.7 Future Market Outlook

2. Disease & Epidemiology Analysis

• 2.1 Introduction to Duchenne Muscular Dystrophy
  • 2.1.1 Disease Definition and Pathophysiology
  • 2.1.2 Genetic Basis and Dystrophin Gene Mutations
  • 2.1.3 Disease Progression and Clinical Manifestations
  • 2.1.4 Disease Burden and Unmet Needs
• 2.2 Etiology and Risk Factors
  • 2.2.1 Inherited Mutations
  • 2.2.2 De Novo Mutations
  • 2.2.3 Family History Assessment
• 2.3 Diagnosis and Screening Landscape
  • 2.3.1 Clinical Evaluation
  • 2.3.2 Genetic Testing Approaches
  • 2.3.3 Biomarker Assessment
  • 2.3.4 Newborn Screening Initiatives
• 2.4 Epidemiology Analysis
  • 2.4.1 Global Prevalence
  • 2.4.2 Global Incidence
  • 2.4.3 Age-Specific Patient Population
  • 2.4.4 Mutation-Specific Patient Distribution
  • 2.4.5 Ambulatory vs Non-Ambulatory Population
  • 2.4.6 Diagnosed and Treatable Patient Population
• 2.5 Epidemiology Forecast

3. Market Dynamics

• 3.1 Market Drivers
  • 3.1.1 Rising Diagnosis Rates
  • 3.1.2 Expanding Genetic Testing Adoption
  • 3.1.3 Advancements in Gene Therapy Technologies
  • 3.1.4 Increasing Rare Disease Funding
  • 3.1.5 Regulatory Incentives for Orphan Drugs
• 3.2 Market Restraints
  • 3.2.1 High Therapy Costs
  • 3.2.2 Limited Eligible Patient Populations
  • 3.2.3 Long-Term Safety Concerns
  • 3.2.4 Reimbursement Challenges
  • 3.2.5 Manufacturing Complexity
• 3.3 Market Opportunities
  • 3.3.1 Next-Generation Gene Therapies
  • 3.3.2 Genome Editing Technologies
  • 3.3.3 Cell-Based Therapeutic Approaches
  • 3.3.4 Combination Treatment Strategies
  • 3.3.5 Emerging Market Expansion
• 3.4 Market Challenges
  • 3.4.1 Clinical Trial Recruitment
  • 3.4.2 Long-Term Outcome Validation
  • 3.4.3 Regulatory Heterogeneity
  • 3.4.4 Access and Affordability Issues

4. Commercial & Market Access

• 4.1 Market Access Overview
• 4.2 Pricing Analysis of Approved Therapies
• 4.3 Reimbursement Landscape
• 4.4 Health Technology Assessment Trends
• 4.5 Rare Disease Funding Programs
• 4.6 Patient Assistance Programs
• 4.7 Commercialization Challenges
• 4.8 Stakeholder Analysis

5. Innovation & Pipeline Landscape

• 5.1 Overview of Emerging Therapeutic Technologies
• 5.2 Pipeline Distribution by Development Stage
  • 5.2.1 Discovery Stage
  • 5.2.2 Preclinical Stage
  • 5.2.3 Phase I
  • 5.2.4 Phase II
  • 5.2.5 Phase III
  • 5.2.6 Regulatory Review Stage
• 5.3 Pipeline Analysis by Modality
  • 5.3.1 Gene Therapy
  • 5.3.2 Exon Skipping Therapies
  • 5.3.3 Gene Editing Therapies
  • 5.3.4 Cell Therapies
  • 5.3.5 Anti-Fibrotic Therapies
  • 5.3.6 Muscle Regeneration Therapies
  • 5.3.7 Small Molecules
• 5.4 Pipeline Analysis by Mechanism of Action
  • 5.4.1 Micro-Dystrophin Gene Replacement
  • 5.4.2 Exon 45 Skipping
  • 5.4.3 Exon 51 Skipping
  • 5.4.4 Exon 53 Skipping
  • 5.4.5 Histone Deacetylase Inhibition
  • 5.4.6 Muscle Regeneration Modulation
  • 5.4.7 CRISPR-Based Gene Editing
• 5.5 Clinical Trial Landscape
  • 5.5.1 Active Clinical Trials
  • 5.5.2 Recruiting Studies
  • 5.5.3 Completed Studies
  • 5.5.4 Terminated and Suspended Studies
• 5.6 Emerging Technology Assessment
• 5.7 Licensing, Collaborations, and Partnerships
• 5.8 Mergers and Acquisitions Activity

6. Treatment Landscape

• 6.1 Current Standard of Care
• 6.2 Treatment Guidelines Overview
• 6.3 Approved Drug Landscape
• 6.4 Corticosteroid Therapies
  • 6.4.1 Deflazacort (Emflaza)
  • 6.4.2 Vamorolone (Agamree)
• 6.5 Exon Skipping Therapies
  • 6.5.1 Eteplirsen (Exondys 51)
  • 6.5.2 Golodirsen (Vyondys 53)
  • 6.5.3 Casimersen (Amondys 45)
  • 6.5.4 Viltolarsen (Viltepso)
• 6.6 Gene Therapy Landscape
  • 6.6.1 Delandistrogene Moxeparvovec (Elevidys)
• 6.7 Non-Steroidal Disease-Modifying Therapies
  • 6.7.1 Givinostat (Duvyzat)
• 6.8 Supportive Care Management
  • 6.8.1 Cardiac Management
  • 6.8.2 Respiratory Management
  • 6.8.3 Orthopedic Management
  • 6.8.4 Rehabilitation and Physical Therapy
• 6.9 Treatment Algorithm Analysis

7. Global Duchenne Muscular Dystrophy Emerging Therapies Report Size & Forecast

• 7.1 Market Definition and Scope
• 7.2 Historical Market Analysis
• 7.3 Global Market Size Analysis (2020-2025)
• 7.4 Global Market Forecast (2026-2035)
• 7.5 Revenue Forecast by Therapy Class
• 7.6 Revenue Forecast by Route of Administration
• 7.7 Revenue Forecast by Distribution Channel
• 7.8 Revenue Forecast by Geography
• 7.9 Scenario Analysis
• 7.10 Market Attractiveness Assessment

8. Global Duchenne Muscular Dystrophy Emerging Therapies Report Segmentation

• 8.1 By Therapy Type
  • 8.1.1 Exon Skipping Therapies
  • 8.1.2 Gene Therapies
  • 8.1.3 Molecule Therapies
  • 8.1.4 Other Emerging Therapies
• 8.3 By Route of Administration
  • 8.3.1 Intravenous
  • 8.3.2 Oral
  • 8.3.3 Other Routes
• 8.4 By End User
  • 8.4.1 Hospitals
  • 8.4.2 Specialty Clinics
  • 8.4.3 Academic Medical Centers
• 8.5 By Distribution Channel
  • 8.5.1 Hospital Pharmacies
  • 8.5.3 Retail Pharmacies & Specialty Pharmacies

9. Geographical Analysis (Regional Level)

• 9.1 North America
  • 9.1.1 Market Size and Forecast
  • 9.1.2 Demand Drivers
  • 9.1.3 Regional Regulatory Overview
  • 9.1.4 Competitive Intensity
• 9.2 Europe
  • 9.2.1 Market Size and Forecast
  • 9.2.2 Demand Drivers
  • 9.2.3 Regional Regulatory Overview
  • 9.2.4 Competitive Intensity
• 9.3 Asia-Pacific
  • 9.3.1 Market Size and Forecast
  • 9.3.2 Demand Drivers
  • 9.3.3 Regional Regulatory Overview
  • 9.3.4 Competitive Intensity
• 9.4 Latin America
  • 9.4.1 Market Size and Forecast
  • 9.4.2 Demand Drivers
  • 9.4.3 Regional Regulatory Overview
  • 9.4.4 Competitive Intensity
• 9.5 Middle East & Africa
  • 9.5.1 Market Size and Forecast
  • 9.5.2 Demand Drivers
  • 9.5.3 Regional Regulatory Overview
  • 9.5.4 Competitive Intensity

10. Key Countries Analysis

• 10.1 United States
  • 10.1.1 Market Size
  • 10.1.2 Epidemiology Analysis
  • 10.1.3 Regulatory Framework
  • 10.1.4 Reimbursement Environment
  • 10.1.5 Key Companies and Product Presence
• 10.2 Canada
• 10.3 Germany
• 10.4 United Kingdom
• 10.5 France
• 10.6 Italy
• 10.7 Spain
• 10.8 China
• 10.9 Japan
• 10.10 India
• 10.11 South Korea
• 10.12 Australia
• 10.13 Brazil
• 10.14 Mexico
• 10.15 Saudi Arabia
• 10.16 South Africa

11. Regulatory & Policy Landscape

• 11.1 Regulatory Overview for Rare Diseases
• 11.2 Orphan Drug Designation Frameworks
• 11.3 United States Regulatory Framework
  • 11.3.1 FDA Approval Pathways
  • 11.3.2 Accelerated Approval Programs
  • 11.3.3 Rare Pediatric Disease Programs
• 11.4 Europe Regulatory Framework
  • 11.4.1 EMA Approval Pathways
  • 11.4.2 Orphan Medicinal Product Framework
• 11.5 Japan Regulatory Framework
  • 11.5.1 PMDA Review Pathways
  • 11.5.2 Sakigake and Orphan Programs
• 11.6 India Regulatory Framework
  • 11.6.1 CDSCO Approval Process
  • 11.6.2 Rare Disease Policy Environment
• 11.7 China Regulatory Framework
  • 11.7.1 NMPA Approval Pathways
  • 11.7.2 Rare Disease Incentives
• 11.8 Gene Therapy Regulatory Considerations
• 11.9 Pharmacovigilance Requirements
• 11.10 Intellectual Property Landscape

12. Competitive Landscape

• 12.1 Market Structure Analysis
• 12.2 Competitive Benchmarking
• 12.3 Market Share Analysis
• 12.4 Product Positioning Matrix
• 12.5 Pipeline Competitiveness Assessment
• 12.6 Strategic Developments
  • 12.6.1 Collaborations and Partnerships
  • 12.6.2 Licensing Agreements
  • 12.6.3 Acquisitions and Investments
  • 12.6.4 Clinical Trial Expansions
• 12.7 SWOT Analysis
• 12.8 Porter's Five Forces Analysis

13. Company Profiles

• 13.1 Sarepta Therapeutics
  • 13.1.1 Company Overview
  • 13.1.2 Approved Products
  • 13.1.3 Key Indications
  • 13.1.4 Verified DMD Pipeline Assets
  • 13.1.5 Strategic Outlook
• 13.2 NS Pharma
  • 13.2.1 Company Overview
  • 13.2.2 Approved Product
  • 13.2.3 Key Indications
  • 13.2.4 Verified Pipeline
  • 13.2.5 Strategic Outlook
• 13.3 Capricor Therapeutics
  • 13.3.1 Company Overview
  • 13.3.2 Approved Product
  • 13.3.3 Key Indications
  • 13.3.4 Verified Pipeline
  • 13.3.5 Strategic Outlook
• 13.4 Wave Life Sciences
  • 13.4.1 Company Overview
  • 13.4.2 Approved Product
  • 13.4.3 Key Indications
  • 13.4.4 Pipeline Assets
  • 13.4.5 Strategic Outlook
• 13.5 Santhera Pharmaceuticals
  • 13.5.1 Company Overview
  • 13.5.2 Approved Product Linkage
  • 13.5.3 Key Indications
  • 13.5.4 Pipeline Assets
  • 13.5.5 Strategic Outlook
• 13.6 Pfizer
  • 13.6.1 Company Overview
  • 13.6.2 DMD Development Programs
  • 13.6.3 Clinical Development Status
  • 13.6.4 Strategic Outlook
• 13.7 REGENXBIO
  • 13.7.1 Company Overview
  • 13.7.2 DMD Development Programs
  • 13.7.3 Clinical Development Status
  • 13.7.4 Strategic Outlook
• 13.8 Satellos Bioscience
  • 13.8.1 Company Overview
  • 13.8.2 DMD Pipeline Programs
  • 13.8.3 Clinical Development Status
  • 13.8.4 Strategic Outlook
• 13.9 Ultragenyx Pharmaceutical
  • 13.9.1 Company Overview
  • 13.9.2 DMD Pipeline Programs
  • 13.9.3 Clinical Development Status
  • 13.9.4 Strategic Outlook
• 13.10 Satellos Bioscience
  • 13.10.1 Company Overview
  • 13.10.2 DMD Pipeline Programs
  • 13.10.3 Clinical Development Status
  • 13.10.4 Strategic Outlook

14. Future Outlook

• 14.1 Future Evolution of the DMD Therapeutics Market
• 14.2 Emerging Technology Trends
• 14.3 Future Regulatory Developments
• 14.4 Competitive Outlook Through 2035
• 14.5 Commercial Opportunity Assessment
• 14.6 Analyst Recommendations

15. Methodology

• 15.1 Research Objectives
• 15.2 Research Design
• 15.3 Secondary Research Sources
• 15.4 Primary Research Methodology
• 15.5 Epidemiology Modeling Approach
• 15.6 Market Forecasting Methodology
• 15.7 Data Validation Framework
• 15.8 Assumptions and Limitations
• 15.9 Abbreviations and Definitions